Geron Corp (GERN) Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology
June 17, 2021 4:30 PM EDTResults reinforce imetelstats novel approach to the treatment of myelofibrosis (MF)
Data support ongoing IMpactMF Phase 3 clinical trial
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. The publication highlights the clinical benefits observed in the study, including symptom... More